Nektar Therapeutics (NASDAQ:NKTR)

37.65
Delayed Data
As of 4:00pm ET
 +0.30 / +0.80%
Today’s Change
33.50
Today|||52-Week Range
111.36
-36.96%
Year-to-Date
Nektar (NKTR) Catches Eye: Stock Jumps 8.7%
Nov 13 / Zacks.com - Paid Partner Content
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
Nov 07 / Zacks.com - Paid Partner Content
Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up
Nov 08 / Zacks.com - Paid Partner Content
What's in the Cards for Nektar (NKTR) This Earnings Season?
Nov 05 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close37.35
Today’s open37.43
Day’s range37.01 - 38.54
Volume3,094,426
Average volume (3 months)2,257,568
Market cap$6.5B
Data as of 4:00pm ET, 11/14/2018

Growth & Valuation

Earnings growth (last year)+43.64%
Earnings growth (this year)+726.77%
Earnings growth (next 5 years)-7.38%
Revenue growth (last year)+86.00%
P/E ratio9.1
Price/Sales30.27
Price/Book67.84

Competitors

 Today’s
change
Today’s
% change
BLUEbluebird bio Inc-3.79-3.15%
TECHBio-Techne Corp-0.55-0.34%
EXASExact Sciences Corp-0.96-1.38%
NBIXNeurocrine Bioscienc...-13.37-13.44%
Data as of 4:00pm ET, 11/14/2018

Financials

Next reporting dateFebruary 28, 2019
EPS forecast (this quarter)-$0.63
Annual revenue (last year)$307.7M
Annual profit (last year)-$96.7M
Net profit margin-31.42%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Howard W. Robin
Chief Operating Officer &
Senior Vice President
John Nicholson
Corporate headquarters
San Francisco, California

Forecasts